PELVICOL 2CM X 7CM 1.0MM
Report
- Report Number
- 9617613-2016-00002
- Event Type
- Injury
- Date Received
- May 10, 2016
- Date of Event
- January 17, 2008
- Report Date
- February 24, 2016
- Manufacturer
- COVIDIEN, FORMERLY TISSUE SCIENCE LABOR
- Product Code
- FTL
- PMA / PMN Number
- K992556
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- MO, US
- Reporter Occupation
- OTHER
Narratives
REFERENCE NUMBER: (B)(4). EXEMPTION NUMBER: E2013003. COVIDIEN IS SUBMITTING THIS REPORT ON BEHALF OF C.R. BARD, INC., (IMPORTER). BARD'S TRACKING NUMBER: (B)(4). H11: CORRECTED DATA - D4 LOT #; SERIAL # NOT AVAILABLE AS INITIALLY REPORTED.
REFERENCE NUMBER: (B)(4). EXEMPTION NUMBER: E2013003. COVIDIEN IS SUBMITTING THIS REPORT ON BEHALF OF C.R. BARD, INC., (IMPORTER). BARD'S TRACKING NUMBER: (B)(4).
REFERENCE NUMBER: (B)(4). EXEMPTION NUMBER: E2013003. COVIDIEN IS SUBMITTING THIS REPORT ON BEHALF OF C.R. BARD, INC., (IMPORTER). (B)(4).
REFERENCE NUMBER: (B)(4). EXEMPTION NUMBER: E2013003. COVIDIEN IS SUBMITTING THIS REPORT ON BEHALF OF C.R. BARD, INC., (IMPORTER). BARD'S TRACKING NUMBER: (B)(4). H11: CORRECTED DATE - D4 MODEL # AND CATALOG #
REFERENCE NUMBER: (B)(4). EXEMPTION NUMBER: E2013003. COVIDIEN IS SUBMITTING THIS REPORT ON BEHALF OF C.R. BARD, INC., (IMPORTER). BARD'S TRACKING NUMBER: (B)(4).
ACCORDING TO THE REPORTER, THE PATIENT ALLEGED EXPERIENCING AN UNSPECIFIED ADVERSE EVENT AS A RESULT OF THE DEVICE IMPLANTATION.
PER ADDITIONAL INFORMATION RECEIVED, THE PATIENT HAS EXPERIENCED BLOOD LOSS, RECURRENT STRESS/URGE URINARY INCONTINENCE, GRADE 2 CYSTOCELE, PERINEAL LAXITY, PAIN, UNSPECIFIED URINARY PROBLEMS, RECURRENCE, DYSPAREUNIA, VAGINAL SCARRING AND REQUIRED ADDITIONAL SURGICAL AND NON-SURGICAL INTERVENTIONS.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 298193 | PELVICOL 2CM X 7CM 1.0MM | MESH, SURGICAL, POLYMERIC | FTL | COVIDIEN, FORMERLY TISSUE SCIENCE LABOR | 482812 | 07B03-8 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 50 YR | Required Intervention |